AHA

AHA 2025: Low-dose aspirin may cut CV risk in patients with T2DM

November 13, 2025

A preliminary analysis presented at the American Heart Association (AHA) 2025 Scientific Sessions found that adults with T2DM at moderate to high CV risk who took low‑dose aspirin experienced significantly fewer major CV events compared with non‐users. Among ~11,500 patients, MI incidence dropped from 61.2% in non‐users to 42.4% in aspirin users; stroke rates fell from 24.8% to 14.5%; and 10‑year all‑cause mortality decreased from 50.7% to 33.0%. The benefit was more pronounced in patients with better glycemic control and those who adhered consistently—all aspirin‐taking strata showed benefit. Notably, the study excluded individuals with high bleeding risk and didn't capture bleeding events, limiting real‐world applicability. These findings raise important questions for future research and reinforce the need for individualized risk–benefit discussion before prescribing aspirin for primary prevention in diabetes.

Source:

American Heart Association. “Low-dose aspirin linked to lower cardiovascular event risk for adults with Type 2 diabetes.” News release, Nov. 3, 2025. https://newsroom.heart.org/news/low-dose-aspirin-linked-to-lower-cardiovascular-event-risk-for-adults-with-type-2-diabetes